- Home
- PRLD vs ANEB Comparison
PRLD vs ANEB Comparison
Compare PRLD & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- ANEB
- Stock Information
- Founded
- PRLD 2016
- ANEB 2020
- Country
- PRLD United States
- ANEB United States
- Employees
- PRLD N/A
- ANEB N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- ANEB Biotechnology: Pharmaceutical Preparations
- Sector
- PRLD Health Care
- ANEB Health Care
- Exchange
- PRLD Nasdaq
- ANEB Nasdaq
- Market Cap
- PRLD 48.6M
- ANEB 39.0M
- IPO Year
- PRLD 2020
- ANEB 2021
- Fundamental
- Price
- PRLD $0.78
- ANEB $1.68
- Analyst Decision
- PRLD Strong Buy
- ANEB Strong Buy
- Analyst Count
- PRLD 2
- ANEB 2
- Target Price
- PRLD $4.50
- ANEB $5.50
- AVG Volume (30 Days)
- PRLD 221.0K
- ANEB 17.0K
- Earning Date
- PRLD 08-11-2025
- ANEB 05-13-2025
- Dividend Yield
- PRLD N/A
- ANEB N/A
- EPS Growth
- PRLD N/A
- ANEB N/A
- EPS
- PRLD N/A
- ANEB N/A
- Revenue
- PRLD $7,000,000.00
- ANEB N/A
- Revenue This Year
- PRLD N/A
- ANEB N/A
- Revenue Next Year
- PRLD N/A
- ANEB N/A
- P/E Ratio
- PRLD N/A
- ANEB N/A
- Revenue Growth
- PRLD N/A
- ANEB N/A
- 52 Week Low
- PRLD $0.61
- ANEB $0.80
- 52 Week High
- PRLD $6.80
- ANEB $3.08
- Technical
- Relative Strength Index (RSI)
- PRLD 42.16
- ANEB 65.22
- Support Level
- PRLD $0.77
- ANEB $1.36
- Resistance Level
- PRLD $0.84
- ANEB $2.46
- Average True Range (ATR)
- PRLD 0.07
- ANEB 0.26
- MACD
- PRLD -0.02
- ANEB 0.03
- Stochastic Oscillator
- PRLD 16.04
- ANEB 37.20
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.